Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to electroCore, Inc. (Nasdaq: ECOR) SEC filings, offering a detailed view of how the company reports its activities as a commercial-stage bioelectronic medicine and wellness business. electroCore focuses on non-invasive neuromodulation and bioelectronic technologies, including its gammaCore nVNS and Quell neurostimulator prescription products and its Truvaga and TAC-STIM wellness and performance devices.
Through forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q, investors can review discussions of electroCore’s business, risk factors, financial condition, and operating results. Current reports on Form 8-K, several of which are referenced in the input data, disclose material events including quarterly financial results, private placements of common stock to satisfy specific obligations, and changes in the composition and leadership of the board of directors.
Other filings may cover topics such as stockholder votes on charter amendments, advisory votes on executive compensation, and the appointment of new independent directors or committee members. Together, these documents outline electroCore’s governance practices, capital structure developments, and key financial metrics over time.
On Stock Titan, these SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the contents of lengthy reports, highlight important sections of 10-K and 10-Q filings, and clarify the implications of Form 8-K disclosures. Users can also review insider-related filings such as Form 4, where available, to see reported transactions by directors and officers. This combination of primary documents and AI-generated insights is intended to make electroCore’s regulatory record more accessible to a wide range of readers.
electroCore, Inc. reported strong top-line growth but ongoing losses and liquidity risk for the quarter ended March 31, 2026. Net sales rose 43% year over year to $9.6 million, driven mainly by U.S. prescription devices, especially sales to the Department of Veterans Affairs.
Gross margin improved to 87%, yet operating expenses increased to $13.7 million, leading to a net loss of $5.3 million and a stockholders’ deficit of $5.7 million. Cash, cash equivalents and marketable securities totaled $8.8 million, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital or cost reductions.
electroCore, Inc. reported strong first quarter 2026 growth, with net sales of $9.6 million, up about 43% from $6.7 million a year earlier, led by VA prescription gammaCore, Quell Fibromyalgia, and Truvaga wellness products. Gross margin expanded to 87%, lifting gross profit to $8.4 million.
The company still posted a GAAP net loss of $5.3 million, or $0.59 per share, reflecting higher operating expenses, including $1.9 million of one-time leadership transition costs and legal fees. Adjusted EBITDA net loss improved to $2.3 million, and management reaffirmed full-year 2026 revenue growth guidance of about 30% over 2025.
electroCore, Inc. Schedule 13G reports that Hilve Holdings Ltd (and its sole shareholder Mikhail Stiskin) beneficially own 517,522 shares of Common Stock, representing 6.4% of the outstanding shares. The percentage is calculated using 8,083,558 shares outstanding as of March 13, 2026.
The filing states Hilve Holdings Ltd has sole voting and dispositive power over the 517,522 shares. Signature blocks show the report was signed on 05/05/2026 by an authorized director and by Mr. Stiskin.
Charles Schwab Corp. submitted a Form 144 notice relating to proposed sales of common stock by Daniel Goldberger. The excerpt lists a planned sale quantity of 25,000 shares and multiple reported dispositions between 04/10/2026 and 05/04/2026 with per‑trade share counts and associated dollar amounts.
Form 144 filing reports proposed dispositions of Common Stock linked to Charles Schwab Corp. The filing lists 10,000 shares described under "Securities To Be Sold" dated 08/04/2024 as "Compensation For Position of CEO." The excerpt also shows a prior sale of 16,072 shares on 04/10/2026 for $96,753.44 by Daniel Goldberger. The filing lists the issuer address and NASDAQ as the market.
electroCore, Inc. Chief Operating Officer Michael Fox received an equity award of 70,000 shares of common stock, reported as an acquisition at $0.00 per share. Following this grant, he directly holds 70,000 shares.
The award is structured as restricted stock units that vest over three years: one-third on the first anniversary of the grant date and the remaining two-thirds in equal annual installments over the next two years. Vesting requires continued service, with additional protection if his employment ends without “cause” or for “good reason” within two years after a “change in control” under the company’s Executive Severance Policy.
electroCore, Inc. former officer and director Daniel S. Goldberger reported an open-market sale of 16,072 shares of common stock at $6.02 per share. According to the footnotes, the shares were sold solely to cover tax withholding obligations triggered by the vesting and settlement of previously issued RSUs.
After the transaction, Goldberger directly owns 291,471 shares, which include 3,665 newly vested shares and 43,200 RSUs that continue to vest in equal monthly installments of 3,600 RSUs, subject to ongoing consulting under a separation agreement. The filing notes a Section 16(b) claim of $1,182, which he voluntarily paid to electroCore.
electroCore, Inc. Chief Operating Officer Michael Fox has filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting person at the company but does not report any stock transactions or specific holdings in the available data.
Lev Joshua S. reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. reported a new equity award to its CFO and Interim President, Joshua S. Lev. He received 45,000 shares of Common Stock as a grant of Restricted Stock Units (RSUs) that vest in full on December 31, 2026, if he remains in continuous service or meets specified change in control conditions. After this grant, he holds 94,556 shares of Common Stock, including 12,556 shares and 82,000 shares underlying RSUs scheduled to vest between 2026 and 2029, reflecting primarily compensation-based, not open-market, activity.
electroCore, Inc. director Thomas J. Errico exercised warrants to acquire a total of 42,055 shares of common stock, with 22,803 shares exercised at an exercise price of $4.35 per share and 19,252 shares at $6.43 per share.
Following these exercises, his directly owned common stock is reported at 350,071 shares. A footnote explains this includes 259,106 shares owned directly, 1,296 shares held by a family trust, 11,000 shares held by a trust for his benefit, 26,615 unvested shares underlying deferred stock units, and 52,054 shares that have vested from prior deferred stock units.